<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To study the potential role of Delta-like-1 (DLK1) in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), we carried out a series of experiments and found that DLK1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels are dysregulated in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and its overexpression leads to dysfunction of 32D and 3T3 cells </plain></SENT>
<SENT sid="1" pm="."><plain>We conclude that DLK1 dysfunction may contribute to <z:mp ids='MP_0002123'>abnormal hematopoiesis</z:mp> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and may be 1 of the antioncogenes </plain></SENT>
<SENT sid="2" pm="."><plain>Delta-like-1 (DLK1) is frequently expressed at elevated levels in CD34(+) cells from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate its role in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we tested bone marrow samples from a panel of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, or myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, with real-time polymerase chain reaction (PCR) </plain></SENT>
<SENT sid="4" pm="."><plain>We show here that DLK1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels are higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and lower in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients than in healthy individuals </plain></SENT>
<SENT sid="5" pm="."><plain>Myeloid progenitor 32D cells overexpressing DLK1 display <z:mp ids='MP_0006042'>increased apoptosis</z:mp>, reduced differentiation, and <z:mp ids='MP_0000329'>decreased cell number</z:mp> expansion, which is also accompanied by changes in cell cycle progression </plain></SENT>
<SENT sid="6" pm="."><plain>Immortalized fibroblastic 3T3 cells can grow into <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in <z:mp ids='MP_0003815'>nude</z:mp> mice but the size of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are smaller from those overexpressing DLK1 </plain></SENT>
<SENT sid="7" pm="."><plain>These observations suggest that DLK1 dysfunction may contribute to the ineffective hematopoiesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>